Media Thread, page-13931

IMU has already presented HER-Vaxx data for end of Ph2 clinical trial last month and is too expensive to conduct Ph3 given their current cash balance and MC. PH seems to be trying to get the other IP to end of Ph2 or at a stage which will attract BP to sell the lot. I think BP will act early on VAXINIA and onCARlytics at end of Ph1 in 6-9 months time instead of waiting for near or end of Ph2 especially for VAXINIA as it's already demonstrate efficacy which is the primary end point for Ph2.

CMO changes whenever the development stage of the IP changes and IMU has been moving very quickly in their development stage for their multiple platform, there's a synergy between CF33, onCARlytics and Azer-Cel (hence the acquisition 8 months ago) which LC has mentioned.